Fenbendazole cancer treatment is an alternative cancer therapy based on the use of a prescription medication used to treat parasitic infections. According to Joe Tippens’ protocol, the drug is taken at 222 mg per day (one gram) seven days a week in either oral granule form or liquid suspension and taken with food.
According to recent studies, fenbendazole has antitumor effects in cell cultures and animal models. This is attributed to its microtubule depolymerizing effect on cancer cells and its RAS-related signaling pathway inhibitory activity.
It acts on tubulin, a polymer that makes up the mitotic spindle and helps separate the chromosomes during cell division (mitosis). This is a very important process for cellular growth and function. Drugs that interfere with the activity of microtubules block vital cellular functions and are used to kill parasites.
Interestingly, fenbendazole is already an established broad-spectrum benzimidazole anthelmintic drug with proven efficacy against gastrointestinal parasites (pinworms, roundworms, hookworms, giardia, and Taenia solium) in many animal species. Thus, repurposing this drug for cancer treatment represents an attractive strategy for saving time and money in developing novel drugs.
We encapsulated fenbendazole and the mTOR inhibitor, rapamycin, in polymer-based micelles to form a combination formulation. The resulting micelle (M-FR) showed synergistic effects in preventing microtubule polymerization and exhibited a superior colony inhibition in a clonogenic assay. In addition, M-FR has a smaller particle size, a lower zeta potential value, and a slower release profile than free fenbendazole. fenbendazole cancer treatment